Latest Breaking News On - Telix japan - Page 1 : comparemela.com

First Patient Dosed in Japanese Prostate Cancer Imaging Study May 24, 2021 21:04 ET | Source: Telix Pharmaceuticals Limited Telix Pharmaceuticals Limited North Melbourne, AUSTRALIA MELBOURNE, Australia and KYOTO, Japan, May 25, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product TLX591-CDx (Illuccix ®, Kit for the preparation of 68Ga-PSMA-11 injection). The study is an academic collaboration between Telix and Kanazawa University. The study will enroll ten patients with advanced prostate cancer and is the first clinical evaluation of gallium-based PSMA imaging in Japan. The objective is to obtain safety data in a representative Japanese patient population, and to demonstrate that the targeting and biodistribution of TLX591-CDx in Japanese patients

United statesCdx illuccixShintaro nishimuraStewart holmstromChristian behrenbruchKanazawa advanced medical center kadmedicTelix pharmaceuticalsKanazawa universityAustralian securities exchangeInnovative clinical research centerAustralian therapeutic goods administrationEuropean unionCorporate communicationsTelix pharmaceuticals limitedNuclear medicine at kanazawa university hospitalKanazawa university hospital